drugset / Trial / NCT03150368

Extended Use of ModraDoc006/r

NCT03150368

Phase 1 Completed 17 enrolled Modra Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a study for extended use of ModraDoc006/r in patients with advanced solid tumours, available after completed treatment in one of the phase I trials with ModraDoc006/r. The primary goal is to explore the safety of extended use.

Timeline

Start
2017-05-10
Primary completion
2018-05-16
Completion
2019-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 10 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral

Indications